Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11944664 Fibroblast growth factor-21-Fc fusion proteins

Patent 11944664 was granted and assigned to Novartis on April, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Brian R. Boettcher0

Stephen Craig Weldon0

Norio Hamamatsu0

Shari Lynn Caplan0

Stuart Licht0

Douglas S. Daniels0

Date of Patent

April 2, 2024

0

Patent Application Number

174103070

Date Filed

August 24, 2021

0

Patent Citations

US Patent 10076554 FGF21-FC fusion proteins for treating metabolic disorders

0

US Patent 7576190 FGF-21 fusion proteins

0

US Patent 9006400 Fibroblast growth factor-21-Fc fusion proteins

0

US Patent 9023791 Fibroblast growth factor 21 mutations

0

US Patent 9266935 Methods of treating metabolic disorders with an FGF21 variant

0

US Patent 11129874 Nucleic acids encoding FGF21-Fc fusion proteins

0

Patent Primary Examiner

Christine J. Saoud

0

Patent abstract

The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11944664 Fibroblast growth factor-21-Fc fusion proteins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool